Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study

Basit Öğe Kaydı
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKerimoglu, Ulku
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorMusri, Fatma Yalcin
dc.contributor.authorAraz, Murat
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:27:01Z
dc.date.available2024-02-23T14:27:01Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractIntroduction Regorafenib, a receptor tyrosine kinase inhibitor, is a routinely used targeted agent in the current treatment of patients with refractory metastatic colorectal carcinoma (mCRC). The aims of this study were to detect the presence of bowel wall edema during regorafenib treatment via computed tomography (CT) and to assess the relationship between survival and regorafenib-induced bowel wall edema in patients with mCRC receiving regorafenib. Patients and methods We retrospectively evaluated the presence of bowel wall edema on CT of 25 mCRC patients who received regorafenib and analyzed its relationship with progression free survival (PFS) and overall survival (OS). Results Among the 25 patients, 25 had small bowel wall edema (SBWE) and 14 had large bowel wall edema (LBWE) on at least one CT examination. The median SBWE value was 4.85 milimeters (mm). Of the 25 patients, 14 had SBWE <= 4.85 mm and 11 had SBWE >4.85 mm. Regorafenib intolerance was significantly higher at SBWE >4.85 mm patients (p = 0.03). The median PFS was 4.6 months (95% CI: 2.4-6.8) and median OS was 9.3 months (95% CI: 3.1-15.4). Median PFS and OS were shorter in patients with SBWE > 4.85 mm than in those with <= 4.85 mm, but not statistically significant (median PFS: 3.9 vs 4.6 months, p: 0.523; median OS: 5.6 vs 9.3 months, p: 0.977). Conclusions Regorafenib caused SBWE in patients with mCRC. Patients who developed more SBWE had a higher regorafenib intolerance and a shorter survival. Further studies are needed to confirm the predictor value of SBWE on the survival outcomes of patients with mCRC receiving regorafenib.en_US
dc.identifier.doi10.1177/1078155220978471
dc.identifier.endpage1935en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue8en_US
dc.identifier.pmid33283629en_US
dc.identifier.scopus2-s2.0-85097303569en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1929en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220978471
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14424
dc.identifier.volume27en_US
dc.identifier.wosWOS:000627093300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRegorafeniben_US
dc.subjectRegorafenib Intoleranceen_US
dc.subjectSmall Bowel Wall Edemaen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.titleSmall bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu